COMP <GO>
ROIV vs MRK // 10Y YIELD & FRED MACRO BETA
Roivant Sciences Ltd. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: ROIV 2
— MRK 12
▲ 10Y YIELD & FRED MACRO BETA LEADER: ROIV
LAST: $36.91 (-1.63%) • MKT CAP: $27.10B
macro-sensitivity
1.00
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
macro-sensitivity
0.92
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ROIV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ROIV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -14.00% | 20.70% | -34.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.80% | 3.42% | -6.22 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 1.30% | -66.30 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | ROIV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.60% | +0.30 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.3 | 56.9 | -2.57 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.00 | 0.92 | +0.08 | ROIV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 18.4x | +9.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.10B | $361.02B | -$333.92B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ROIV REV | MRK REV | ROIV GROSS % | MRK GROSS % | ROIV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $8.3M | $65.01B | 44.0% | 74.8% | -$758.6M | $12.36B |
| FY 2024 | $29.1M | $64.17B | 44.0% | 76.3% | -$844.0M | $18.10B |
| FY 2023 | $32.7M | $60.12B | 44.0% | 44.0% | -$766.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ROIV // BETA 1.00
MRK // BETA 0.92